RECOMBINANT HUMAN INTERLEUKIN-2 IN PATIENTS WITH INVASIVE THYMOMA

重组人白细胞介素 2 在侵袭性胸腺瘤患者中的应用

• 批准号: 3743129
• 负责人: MICHAEL S GORDON
• 金额: --
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3743129
• 关键词: clinical trials; drug administration rate /duration; drug adverse effect; drug screening /evaluation; human subject; human therapy evaluation; injection /infusion; interleukin 2; neoplasm /cancer immunotherapy; neoplasm /cancer radiodiagnosis; recombinant proteins; self care; thymus neoplasms

A phase II trial where interleukin-2 (IL-2) will be self-administered through injections 5 times a week for a period of 4 weeks. Side effects will be examined and a two week recovery period will follow to recover from any side effects. Response will be evaluated by x-ray test at the conclusion of every 6 week period. If patients respond to IL-2 therapy they will be eligible for a total of 4 cycles for treatment.

白介素2(IL-2)自我给药的II期试验 每周注射5次，为期4周。副作用 将接受检查，随后将有两周的恢复期以恢复 不会有任何副作用。反应将通过x射线测试在 每6周结束一次。如果患者对IL-2治疗有反应 他们将有资格接受总共4个周期的治疗。